Icon times
Alembic Pharma Earnings Call Highlights Jun-21 QuarterFinancial Highlights • Revenue from operations made a slight decline of 1% YOY & rise of 3.5% QOQ and stood at 1326 crores • EBITDA took a major hit with a decline of 39% YOY & 29% QOQ and stood at 254 crores • EBITDA margin also stood at 19% declining 12% YOY & 9% QOQ • PAT got almost halved YOY and declined by 45% YOY and stood at 165 crores, also declining by 34% • PAT margin also followed the same path and stood at 12%, declining by 10% YOY & 7% QOQ • R&D Expenses as a percent of sale stood at 167 crores with 13% of sales being contributed to R&D, with an increment of 2% YOY and an equivalent decline QOQ • Net debt to Equity stood at 0.04 Business Highlights • Revenue Mix: Generics formulations contributed 43% of revenue, branded formulations contributed 36% of revenue & 21% of revenue came from API • US Generics business contributed 369 crores declining 38% YOY from 596 crores. 5-year CAGR stands currently at 24% • EX US Generics sales revenue stood at 197 crores with an increment of 13% YOY from 175 crores. 5-year CAGR currently stands at 25% • API Revenue also contributed 279 crores with an increment of 6% YOY from 264 crores. 5-year CAGR stands at 11% • Branded business contributed 480 crores with an increment of 57% YOY from 342 crores. 5-year CAGR stands at 5% • Out of 43% generics business,28% came from US & 15% from other than US. • India contributed 36% of total revenue with 18% coming from specialty formulations,14% came from Acute Formulations, & 4% from VET API • US Generic: Q1 FY22 :3 ANDA Filings, 5 Final Approvals,2 Products launched in Q1FY22, 6 products are on partner label • Currently Company’s Market share is 1.4% of Indian Pharma space • Company has made an investment of 124 crores in Q1 FY 2022 • Company has withdrawn its EPS guidance of Rs 50 for the year due to softness in US business & additional competition & price erosions as well. Delay in US FDA inspections have also contributed to the same. • Company is still bullish for the US market in long term with a strong conviction • Company is expecting around 15 products in current year • As per the company market share gains will be reflective in Q2 & Q3 • As per the company capex will take 5-7 years for sales to reach peak in US • Generics business surrounds much of uncertainty • As per the company, sector sales to fixed assets ratio is 1.5 to 2 times & company plans to achieve the same in long term • Majority of other expenses in profit & loss account (415 crores) are from domestic markets & these numbers will stay with a volatility up & down of around 10% • As per the company US market is still a very lucrative market to make money with future opportunities to be explored with supply chain management & management • As per the company Indian market is still opening up & normalcy is returning to the market • Prices in US market have declined in Sartan due to various constraints & also other molecules have taken the brunt of pricing competition & majority of products have suffered price erosion • Company expects R&D spend to be around 650 to 700 crores for the full year FY 2022 • Alembic Pharma is expecting 5-10% growth in API business in India

Alembic Pharma Conference Call Highlights Q1 FY22

Published on 29 July 2021 .Views 0 .Comments 0
Share On
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 9,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded

premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
Chat with InvestYadnya